<DOC>
	<DOCNO>NCT02402140</DOCNO>
	<brief_summary>Primary end-point The primary end-point influence pharmaceutical intervention tacrolimus intra-subject variability first 3 month kidney transplant . Coefficients variation calculate average dose-corrected tacrolimus blood concentration ( CV= Standard Deviation ( SD ) x 100/mean ) study visit day 10 , 14 , 21 , 30 , 60 90 post kidney transplant . Secondary end-points 1 . Secondary outcome include evaluate percentage patient achieve target level tacrolimus day study visit 7 , 10 , 14 , 21 , 28 , 60 e 90 day kidney transplant ; 2 . Tacrolimus bioavailability profile period 3 month , characterize mean standard deviation ( SD ) dose correct tacrolimus blood concentration ( ng/ml/mg ) ; 3 . Assess patient adherence validate questionnaire `` Portuguese version Basel Scale Adherence Rating Immunosuppressive Drugs ( BAASIS ) scale '' . It consist four-item questionnaire measure nonadherence immunosuppressive past four week . This questionnaire assess omission single dos successive dos , time deviation &gt; 2h dose reduction . Responses give six-point scale : never , per month , every second week , every week , per week every day . Patients answer different `` never '' four question consider nonadherent ; 4 . We evaluate renal function eGFR Modification Diet Renal Disease ( MDRD ) ; 5 . We evaluate Incidence Infections ; 6 . We evaluate Treated acute rejection episode ; 7 . We evaluate Death case ; 8 . We evaluate Graft loss case ; 9 . We evaluate Discontinuation immunosuppressive treatment ; 10 . We evaluate Hospital readmission . Study Design This single-center , prospective , randomize control study evaluate influence pharmaceutical intervention tacrolimus intra-subject variability first 3 month transplantation . The author design protocol , acquire maintain data , conduct statistical analysis . The protocol approve independent ethic committee . All subject sign write informed consent enrollment study conduct accord good clinical practice declaration Helsinki . This study conduct Hospital Rim February 2014 December 2014 , 128 randomize follow 3 month transplantation .</brief_summary>
	<brief_title>Influence Pharmaceutical Care Intraindividual Variability Tacrolimus Concentrations</brief_title>
	<detailed_description>Population Inclusion criterion patient underwent renal transplantation age ≥18 year old , sign informed consent , underwent follow-up post transplant clinic Hospital Rim 3 month , receive immunosuppressive drug tacrolimus , prednisone sodium mycophenolate tacrolimus , azathioprine , prednisone . Exclusion criteria patient underwent second kidney transplant , follow Hospital Rim transplant participate study pharmaceutical intervention . Randomization The randomization plan carry block stratify immunosuppressive drug tacrolimus , prednisone mycophenolate sodium tacrolimus , prednisone azathioprine . Opaque envelope make table random number open day randomization determine group patient allocate group 1 pharmaceutical intervention group 2 without pharmaceutical intervention .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>patient underwent renal transplantation age ≥18 year old , sign informed consent , underwent followup post transplant clinic Hospital Rim 3 month , receive immunosuppressive drug tacrolimus , prednisone sodium mycophenolate tacrolimus , azathioprine , prednisone . patient underwent second kidney transplant , follow Hospital Rim transplant participate study pharmaceutical intervention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>tacrolimus blood concentration</keyword>
	<keyword>pharmaceutical intervention</keyword>
	<keyword>intrasubject variability</keyword>
</DOC>